Leucocyte-Rich and Platelet-Rich Fibrin(L-PRF) for the Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) with Long Term Follow-up

Bisphosphonates (BPs), antiresorptive and antiangiogenic drugs are used to prevent metastatic bone cancers and to treat osteoporosis and Paget's disease.Besides BPs, due to the growing number of osteonecrosis cases associated with other antiresorptive and antiangiogenic therapies, American Association of Oral and Maxillofacial Surgeons (AAOMS) recommends changing the terminology of bisphosphonate related osteonecrosis of the jaws (BRONJ) and favors the term medication related osteonecrosis of the jaws (MRONJ) in 2014.The aim of this article was to report to case of a 79-year-old male with using oral ibandronate with osteonecrosis in the left retromolar area of the mandible.The therapeutic approach consisted of debridement of te osteonecrotic area and using leucocyte-rich and platelet-rich fibrin (L-PRF) for the treatment of medication-related osteonecrosis of the jaw (MRONJ).